{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:02:37Z","timestamp":1788991357374,"version":"build-2803163510"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 82270619"],"award-info":[{"award-number":["NSFC 82270619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 82470621"],"award-info":[{"award-number":["NSFC 82470621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Antibody-drug conjugates (ADCs) are rapidly developing targeted cancer therapeutic agents that combine specific monoclonal antibodies with cytotoxic agents. Currently, 17 ADCs are approved for the global market for treating hematological and solid tumors with more than 100 ADCs are in phase III clinical trials. ADC-induced hepatotoxicity is a significant concern with unclear mechanisms, and the incidence of hepatic adverse events (AEs) varies across different ADCs. Most hepatic AEs are moderate; however, some ADCs can cause life threatening or fatal AEs. The management of hepatic AEs is limited and is mainly based on product labeling information and the recommendations of study investigators. Therefore, it is critical to raise awareness among oncologists regarding ADC-related hepatotoxicity, and collaboration between oncologists and hepatologists is recommended to provide effective support. This review is the first to focus the hepatotoxicity of ADC, provide an overview of approved ADCs, summarize the potential mechanisms underlying hepatotoxicity, discuss the hepatic toxicities reported in clinical trials and postmarketing studies, and integrate the current recommended management strategies. This article will serve as a valuable resource for medical practitioners in comprehending and managing ADC-related hepatotoxicity, while facilitating further considerations regarding the clinical application of these novel agents.<\/jats:p>","DOI":"10.3389\/fphar.2025.1694436","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:45:45Z","timestamp":1764924345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence"],"prefix":"10.3389","volume":"16","author":[{"given":"Yinuo","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/s2352-3026(23)00345-9","article-title":"Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"11","author":"Abrisqueta","year":"2024","journal-title":"Lancet Haematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"E1926","DOI":"10.1073\/pnas.1714377115","article-title":"Endocytosis as a stabilizing mechanism for tissue homeostasis","volume":"115","author":"Adler","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B3","unstructured":"FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer\n          \n          \n          2025"},{"key":"B4","unstructured":"FDA adverse events reporting system (FAERS) public dashboard\n          \n          \n          2025"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm. Res."},{"key":"B7","unstructured":"A study to evaluate enfortumab vedotin versus (vs) chemotherapy in subjects with previously treated locally advanced or metastatic urothelial cancer (EV-301)\n          \n          \n          2025"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/bjh.17333","article-title":"Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series","volume":"193","author":"Brivio","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/s1470-2045(21)00139-x","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3324\/haematol.2023.283459","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4155\/bio-2018-0259","article-title":"Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials","volume":"11","author":"Carrasco-Triguero","year":"2019","journal-title":"Bioanalysis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","article-title":"Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents","volume":"58","author":"Casi","year":"2015","journal-title":"J. Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.Can-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/dddt.S83592","article-title":"Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","article-title":"HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/s1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory hodgkin's lymphoma (AHOD1221): a Children's oncology group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2042098620915058","DOI":"10.1177\/2042098620915058","article-title":"Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis","volume":"11","author":"Cobert","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"B24","unstructured":"Institute NCINC\n          \n          \n          2017"},{"key":"B25","unstructured":"INC. S. TIVDAK- tisotumab vedotin injection, powder, for solution"},{"key":"B26","doi-asserted-by":"publisher","first-page":"103853","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2024","journal-title":"Breast"},{"key":"B27","unstructured":"Wyeth pharmaceuticals LLC asoPI. BESPONSA-inotuzumab ozogamicin injection, powder, lyophilized, for solution\n          \n          \n          2024"},{"key":"B28","unstructured":"INC. S. ADCETRIS- brentuximab vedotin injection, powder, lyophilized, for solution"},{"key":"B29","unstructured":"INC S. PADCEV EJFV- enfortumab vedotin injection, powder, lyophilized, for solution"},{"key":"B30","unstructured":"Gilead sciences I. TRODELVY- sacituzumab govitecan powder, for solution"},{"key":"B31","unstructured":"ImmunoGen IRP. ELAHERE-mirvetuximab soravtansine injection, solution"},{"key":"B32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"DeeksVedotin","year":"2021","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/s2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/s2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B38","doi-asserted-by":"publisher","first-page":"37200","DOI":"10.18632\/oncotarget.26461","article-title":"Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes","volume":"9","author":"Endo","year":"2018","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B40","unstructured":"Trastuzumab deruxtecan"},{"key":"B41","unstructured":"Tisotumab vedotin"},{"key":"B42","unstructured":"Mirvetuximab soravtansine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/apt.18271","article-title":"Review article: recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients","volume":"60","author":"Fettiplace","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00277-023-05495-w","article-title":"Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"103","author":"Fischer","year":"2024","journal-title":"Ann. Hematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/jco.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14740338.2020.1718103","article-title":"Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis","volume":"19","author":"Gao","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1159\/000521933","article-title":"Trastuzumab emtansine-induced nodular regenerative hyperplasia: is dose reduction enough as a preventable measure?","volume":"40","author":"Garrido","year":"2022","journal-title":"Dig. Dis."},{"key":"B49","unstructured":"KADCYLA-ado-trastuzumab emtansine injection, powder, lyophilized, for solution\n          \n          \n          2024"},{"key":"B50","unstructured":"I. POLIVY- polatuzumab vedotin injection, powder, lyophilized, for solution\n          \n          \n          2025"},{"key":"B51","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","article-title":"Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake","volume":"62","author":"Gorovits","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/jco.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-Mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/jcpt.13777","article-title":"Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study","volume":"47","author":"Guo","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab soravtansine: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00259-025-07106-4","article-title":"Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (trodelvy) for imaging in gastric cancer and triple-negative breast cancer","volume":"52","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12185-021-03217-4","article-title":"A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation","volume":"115","author":"Izumi","year":"2022","journal-title":"Int. J. Hematol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/s2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/jco.2011.40.5902","article-title":"A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ajh.20432","article-title":"Possible association between budd-chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia","volume":"80","author":"Kurt","year":"2005","journal-title":"Am. J. Hematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2710.2006.00742.x","article-title":"Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report","volume":"31","author":"Lannoy","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41409-025-02598-y","article-title":"Management of liver sinusoidal obstruction syndrome\/veno-occlusive disease in adults: a 2025 perspective from an international expert group","volume":"60","author":"Larue","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab tesirine: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"B70","doi-asserted-by":"publisher","first-page":"20406207211066176","DOI":"10.1177\/20406207211066176","article-title":"Hepatic venoocclusive disease\/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy","volume":"12","author":"Lee","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.5604\/01.3001.0012.7207","article-title":"Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?","volume":"17","author":"Lepelley","year":"2018","journal-title":"Ann. Hepatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/annonc\/mdt566","article-title":"Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials","volume":"25","author":"Li","year":"2014","journal-title":"Ann. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/j.clml.2020.12.008","article-title":"Efficacy and safety of inotuzumab ozogamicin (CMC-544) for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-hodgkin lymphoma: a systematic review and meta-analysis","volume":"21","author":"Li","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1084\/jem.189.12.1961","article-title":"Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells","volume":"189","author":"Linehan","year":"1999","journal-title":"J. Exp. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/17512433.2022.2121704","article-title":"Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials","volume":"15","author":"Liu","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1283247","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2147\/ijn.S501689","article-title":"Utility of (131)I-HLX58-Der for the precision treatment: evaluation of a preclinical radio-antibody-drug-conjugate approach in mouse models","volume":"20","author":"Liu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"L\u00f3pez","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.leukres.2011.01.025","article-title":"Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?","volume":"35","author":"Maniecki","year":"2011","journal-title":"Leuk. Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B85","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.annemergmed.2024.10.015","article-title":"Antibody-drug conjugates: the toxicities and adverse effects that emergency physicians must know","volume":"85","author":"Markides","year":"2025","journal-title":"Ann. Emerg. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/hep.30222","article-title":"Liver complications following treatment of hematologic malignancy with Anti-CD22-Calicheamicin (inotuzumab ozogamicin)","volume":"69","author":"McDonald","year":"2019","journal-title":"Hepatology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"McKertish","year":"2021","journal-title":"Biomedicines"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/jog.16126","article-title":"Safety and efficacy of tisotumab vedotin with cervical cancers: a systematic review and meta-analysis","volume":"50","author":"Mokresh","year":"2024","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","article-title":"Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies","volume":"28","author":"Mustafayev","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B92","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17474086.2020.1740084","article-title":"Monoclonal antibodies in relapsed\/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses","volume":"13","author":"Musto","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1080\/10428194.2019.1579321","article-title":"Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy","volume":"60","author":"Neeman","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B94","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-023-11735-z","article-title":"Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study","volume":"23","author":"Nie","year":"2023","journal-title":"BMC Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1434492","DOI":"10.3389\/fonc.2024.1434492","article-title":"Hepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series","volume":"14","author":"O'Sullivan","year":"2024","journal-title":"Front. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"B99","unstructured":"Combination chemotherapy with or without gemtuzumab in treating young patients with newly diagnosed acute myeloid leukemia\n          \n          \n          2025"},{"key":"B100","unstructured":"A trial of tisotumab vedotin in cervical cancer\n          \n          \n          2025"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1268993","DOI":"10.3389\/fimmu.2023.1268993","article-title":"Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish pediatric leukemia and lymphoma study group experience","volume":"14","author":"Pawinska-Wasikowska","year":"2023","journal-title":"Front. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun. (Lond)."},{"key":"B103","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.Can-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-hodgkin's lymphoma: target and linker-drug selection","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"B107","unstructured":"Disitamab vedotin for injection\n          \n          \n          2025"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun. (Lond)"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/jco.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-Positive\/Human epidermal growth factor receptor 2-Negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s0140-6736(23)01245-x","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev-immunol-031210-101352","article-title":"Signaling by myeloid C-type lectin receptors in immunity and homeostasis","volume":"30","author":"Sancho","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1046\/j.1365-2141.2003.04667.x","article-title":"Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide","volume":"123","author":"Saviola","year":"2003","journal-title":"Br. J. Haematol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.Ccr-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-Targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/jco.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"eabi7083","DOI":"10.1126\/sciimmunol.abi7083","article-title":"Resident kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy","volume":"6","author":"Siwicki","year":"2021","journal-title":"Sci. Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40425-014-0029-x","article-title":"The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer","volume":"2","author":"Stewart","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41409-021-01546-w","article-title":"Low incidence of hepatic sinusoidal obstruction syndrome\/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin","volume":"57","author":"Stutz","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B120","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/sj.bmt.1703242","article-title":"Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia","volume":"28","author":"Tack","year":"2001","journal-title":"Bone Marrow Transpl."},{"key":"B121","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"102806","DOI":"10.1016\/j.ctrv.2024.102806","article-title":"Antibody-drug conjugates for hepato-pancreato-biliary malignancies: \u201cmagic bullets\u201d to the rescue?","volume":"129","author":"Theocharopoulos","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B124","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/s1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1186\/s12885-023-11593-9","article-title":"RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/cad.0000000000001449","article-title":"Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Anticancer Drugs"},{"key":"B128","doi-asserted-by":"publisher","first-page":"104230","DOI":"10.1016\/j.critrevonc.2023.104230","article-title":"Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis","volume":"194","author":"Wang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"123502","DOI":"10.1016\/j.biomaterials.2025.123502","article-title":"Amplifying tumor recognition and drug susceptibility by multivalent ApDC assembly to combat with tumor cell heterogeneity","volume":"324","author":"Wang","year":"2026","journal-title":"Biomaterials"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B131","unstructured":"MYLOTARG-gemtuzumab ozogamicin injection, powder, lyophilized, for solution\n          \n          \n          2021"},{"key":"B132","doi-asserted-by":"publisher","first-page":"683595","DOI":"10.3389\/fimmu.2021.683595","article-title":"Clinical benefits and safety of gemtuzumab ozogamicin in treating acute Myeloid leukemia in various subgroups: an updated systematic review, Meta-analysis, and network meta-analysis","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/17512433.2023.2262673","article-title":"The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis","volume":"16","author":"Xu","year":"","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"","journal-title":"Int. J. Cancer"},{"key":"B135","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14740338.2024.2348572","article-title":"A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin","volume":"24","author":"Xu","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B136","doi-asserted-by":"publisher","first-page":"e37544","DOI":"10.1016\/j.heliyon.2024.e37544","article-title":"Risk analysis of enfortumab vedotin: a real-world approach based on the FAERS database","volume":"10","author":"Zheng","year":"2024","journal-title":"Heliyon"},{"key":"B137","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.18632\/aging.205382","article-title":"Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study","volume":"15","author":"Zhou","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"B138","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1694436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:45:48Z","timestamp":1764924348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1694436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":139,"alternative-id":["10.3389\/fphar.2025.1694436"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1694436","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1694436"}}